CHF 0.00
In stock
SYN-3029-M0011 mgCHF 128.00
SYN-3029-M0055 mgCHF 255.00
SYN-3029-M01010 mgCHF 454.00
SYN-3029-M05050 mgCHF 1'206.00
SYN-3029-M100100 mgINQ
More Information
Product Details
Synonyms JNJ-26481585
Product Type Chemical
Formula C21H26N6O2
MW 394.5
CAS 875320-29-9
Purity Chemicals ≥95%
Appearance Solid.
Solubility Soluble in DMSO.
Declaration Manufactured by SynKinase.
Other Product Data Target: HDAC1, 2, 4, 10 and HDAC11 | Kinase Group: N/A | Substrate: N/A
Shipping and Handling
Shipping AMBIENT
Short Term Storage +4°C
Long Term Storage -20°C
Use/Stability Stable for at least 2 years after receipt when stored at -20°C.
MSDS Inquire
Product Specification Sheet
Datasheet Download PDF

Quisinostat (JNJ-26481585) is a novel second-generation panHDAC inhibitor of HDAC1, 2, 4, 10 and 11. Its highest potency is against HDAC1 with an IC50 of 0.11nM. It has only modest potency against HDACs 2, 4, 10, and 11 (IC50 ranging from 0.33nM to 0.64nM). It has low activity against HDACs 3, 5, 8, and 9 and its lowest potency is against HDACs 6 and 7.

Product References
  1. JNJ-26481585, a novel "second-generation" oral histone deacetylase inhibitor, shows broad-spectrum preclinical antitumoral activity: J. Arts, et al.; Clin. Cancer Res. 15, 6841 (2009)
  2. Preclinical anti-myeloma activity of the novel HDAC-inhibitor JNJ-26481585: T. Stuehmer, et al.; Br. J. Haematol. 149, 529 (2010)
© 2017 Adipogen Life Sciences. Pictures: © 2012 Martin Oeggerli. All Rights Reserved.